ClinicalTrials.gg
Sign In
Active, not recruitingNCT07810972Updated Sep 9, 2026

Evaluate the Safety and Efficacy of TJO-087

A Phase 2 interventional study of TJO-087 and TJO-087 in Dry Eye Syndrome (DES), sponsored by Taejoon Pharmaceutical Co., Ltd.. Active, not recruiting at 1 site in South Korea. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Taejoon Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Apr 2026, registered Sep 2026).
Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

This study aims to evaluate the therapeutic efficacy and safety of investigational product compared with placebo in adult patients with dry eye disease. Patients will receive investigational product or placebo for 3 months, and the therapeutic effect will be assessed based on the change in corneal staining score from baseline.

02

Conditions studied

  • Dry Eye Syndrome (DES)

Browse trials for

Keywords

  • Dry eye syndrome
03

In context

Dry Eye Syndromes

1,366 studies on the registry are indexed under Dry Eye Syndromes; 207 are open to participants now.

This study's enrollment of 90 is above the median of 60 across 1,129 interventional studies indexed under Dry Eye Syndromes.

Browse Dry Eye Syndromes studies →

Lead sponsor

Taejoon Pharmaceutical Co., Ltd. is the lead sponsor of 16 studies on the registry; 1 is open to participants now.

Browse Taejoon Pharmaceutical Co., Ltd. studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged ≥20 years (male or female)
  • Patients with dry eye symptoms
  • Fluorescein corneal staining score(NEI scale) ≥4
  • Schirmer test result (without anesthesia) ≤10 mm/5 min in
  • Tear film break-up time (TBUT) \<10 seconds

Exclusion criteria

Exclusion Criteria:

  • Presence or history of systemic or ocular disorder or condition that could affect the interpretation of study results
  • Intraocular pressure (IOP) >21 mmHg
  • Planned use of contact lenses during the study period
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Experimental group A

    Investigational product QD

    Drug: TJO-087

  • Experimental
    Experimental group B

    Investigational product BID

    Drug: TJO-087

  • Placebo comparator
    Placebo

    Placebo BID

    Drug: Vehicle (Placebo solution)

Interventions

  • DrugTJO-087

    one drop in each eye, twice daily (1 drop of IP, 1 drop of placebo)

  • DrugTJO-087

    one drop in each eye, twice daily (2 dose of IP)

  • DrugVehicle (Placebo solution)

    one drop in each eye, twice daily (2 dose of placebo)

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Corneal Staining Score at 12 weeks

    Change from Baseline in corneal staining using blue fluorescein staining procedure at 12 weeks.

    Time frame: Week 12

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Oct 2026, 6 months after the start.

Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's planned 6 months is below that.

Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2026
First posted
Sep 9, 2026
StartActual
Apr 6, 2026
Primary completionEst.
Oct 2026
CompletionEst.
Dec 2026
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07810972
Lead sponsor
Taejoon Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Sep 9, 2026
Start date
Apr 6, 2026
Primary completion
Oct 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Dry Eye Syndromes →

Other studies from this sponsor

Taejoon Pharmaceutical Co., Ltd. →

Start the discussion